Cell Stem Cell: A new organ-like platform or research that accelerates early lung cancer promises to help develop new potential targeted therapies.

September 14, 2020 // -- In a recent study published in the international journal Cell Stem Cell, scientists from Harvard Medical School and others developed a new accelerated platform that could be used to study lung cancer in the early stages and identify and detect potential new therapies that use organs derived from lung cells to conduct in-depth research.
researchers say organoids can help them track down a common and difficult-to-study lung tumor, pulmonary adenocarcinoma, driven by mutations in the KRAS gene, while the researchers were able to capture molecular changes in tumor progress.
Photo Source: Antonella Dost Lung Cancer is the leading cause of death in the U.S., and the disease is often overlooked at an early stage, although imaging techniques in recent years have made early diagnosis of lung cancer possible, but for early lung cancer, researchers still do not have targeted treatments. In the
study, the researchers used four parallel models of early lung cancer, namely tumor samples from stage 1A lung cancer patients, genetically modified mouse models, lung stem cells derived from mice, or lung organs derived from lung cells produced by human-induced erythrocytes. 'We know very little about early events that convert normal lung cortical cells into cancer cells,' said Kim, a researcher at
. 'In the article, we used early-stage samples from lung cancer patients to find that organ-like organs can truly simulate events in the body of early-stage patients with disease, and within seven days researchers were able to observe these changes from organs, which often take months or more in mice or human patients.'
The researchers then introduced cancer-inducing KRAS mutations into the alveo progenitocytes of lung organs and used single-cell RNA sequencing techniques to see which genes could turn on expression;
KRAS-mutated tumors are often resistant to therapy, and this study may provide researchers with a new way to find new treatments for drug-resistant cancers, although the study focuses on the types of lung cancer driven by KRAS, the researchers believe that this type of organ strategy may promote the study of a variety of types of cancer, including the detection of drug candidates.
researchers say they hope to develop new human and lung organ models for early-stage lung cancer to help develop powerful drug development platforms to help develop new lung cancer treatments.
() Original source: Antonella F. M. Dost, Aaron L. Moye, Marall Vedaie, et al. Organoids Model Executive Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells, Cell Stem Cell (2020). doi:10.1016/j.stem.2020.07.022.